Prostate Cancer Clinical Trials

Showing 1-16 of 16 items
1.
2.
3.
4.
5.
6.
7.
  • Enzalutamide + External Beam Rt For Prostate
  • This research study is evaluating a drug called enzalutamide in combination with external beam radiation therapy as a possible treatment for prostate cancer. Presently, when participants receive hormonal therapy with radiation therapy for prostate cancer, medications are given to reduce testosterone levels in the blood stream. This leads to side effects such as loss of sex drive, erectile dysfunction (ED) and decrease in muscle strength. The purpose of this study is test another form of hormonal therapy with radiation therapy. The medication called enzalutamide will be used with radiation therapy. Instead of lowering testosterone, enzalutamide blocks testosterone in cells. This study will test if enzalutamide when used with radiation will lower the PSA without causing the side effects associated with medications that lower testosterone in the blood stream.
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
8.
  • CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer
  • This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other areas of the body or has not responded to at least one type of treatment. Biological therapies, such as glycosylated recombinant human interleukin-7, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. It is not yet known whether glycosylated recombinant human interleukin-7 works better with or without vaccine therapy in treating prostate cancer.
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
9.
10.
11.
  • Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
  • This research study is evaluating a drug called enzalutamide in metastatatic castration resistant prostate cancer.Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy. The purpose of this study is to analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with Enzalutamide. Prior chemotherapy is not a requirement of this trial. Enzalutamide is a drug designed to block the effects of male hormones in the body that may be helping prostate cancer to grow. It has already been approved by the FDA (the U.S. Food and Drug Administration) for patients with castration-resistant prostate cancer who have received prior chemotherapy. Additionally, this study will analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with enzalutamide.
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
12.
  • A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
  • This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: - LY2452473
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
13.
14.
  • Early Changes In Multiparametric MRI In Prostate Cancer
  • In this research study, the investigators are trying to determine if there are measurable changes in prostate MRI that will help predict those who will or will not respond to Androgen Deprivation Therapy (ADT) and External Beam Radiation Therapy (EBRT) The first baseline prostate MRI prior to the start of treatment is standard of care. The participant's ADT/EBRT treatment is also standard of care, as advised by their doctor. It is the 3 follow up prostate MRIs during ADT/EBRT treatment, and 4 follow up serum PSA levels that are part of this research study.
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
15.
  • Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer
  • The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for low risk, organ-confined prostate cancer, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.
  • Diagnoses: Prostate Cancer
  • Status: Recruiting
16.
Showing 1-16 of 16 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms